vs
景顺（IVZ）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
景顺的季度营收约是瑞思迈的1.2倍（$1.7B vs $1.4B），瑞思迈净利率更高（27.6% vs -58.9%，领先86.5%），瑞思迈同比增速更快（11.0% vs 6.2%），景顺自由现金流更多（$432.2M vs $311.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs 7.1%）
景顺是总部位于美国佐治亚州亚特兰大的独立投资管理企业，在全球20个国家设有分支机构，旗下运营景顺、Invesco Perpetual、PowerShares等品牌，普通股为标普500指数成分股，于纽约证券交易所挂牌交易。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
IVZ vs RMD — 直观对比
营收规模更大
IVZ
是对方的1.2倍
$1.4B
营收增速更快
RMD
高出4.8%
6.2%
净利率更高
RMD
高出86.5%
-58.9%
自由现金流更多
IVZ
多$121.0M
$311.2M
两年增速更快
RMD
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.4B |
| 净利润 | $-995.9M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | -86.2% | 34.6% |
| 净利率 | -58.9% | 27.6% |
| 营收同比 | 6.2% | 11.0% |
| 净利润同比 | -575.8% | 13.9% |
| 每股收益（稀释后） | $-2.61 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IVZRMD
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.5B | $1.2B |
净利润IVZRMD
| Q4 25 | $-995.9M | $392.6M | ||
| Q3 25 | $356.4M | $348.5M | ||
| Q2 25 | $197.4M | $379.7M | ||
| Q1 25 | $171.1M | $365.0M | ||
| Q4 24 | $209.3M | $344.6M | ||
| Q3 24 | $55.0M | $311.4M | ||
| Q2 24 | $132.2M | $292.2M | ||
| Q1 24 | $141.5M | $300.5M |
毛利率IVZRMD
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 57.9% |
营业利润率IVZRMD
| Q4 25 | -86.2% | 34.6% | ||
| Q3 25 | 16.5% | 33.4% | ||
| Q2 25 | 14.1% | 33.7% | ||
| Q1 25 | 18.1% | 33.0% | ||
| Q4 24 | 19.6% | 32.5% | ||
| Q3 24 | 6.6% | 31.6% | ||
| Q2 24 | 13.9% | 31.2% | ||
| Q1 24 | 14.4% | 31.3% |
净利率IVZRMD
| Q4 25 | -58.9% | 27.6% | ||
| Q3 25 | 21.7% | 26.1% | ||
| Q2 25 | 13.0% | 28.2% | ||
| Q1 25 | 11.2% | 28.3% | ||
| Q4 24 | 13.1% | 26.9% | ||
| Q3 24 | 3.6% | 25.4% | ||
| Q2 24 | 8.9% | 23.9% | ||
| Q1 24 | 9.6% | 25.1% |
每股收益（稀释后）IVZRMD
| Q4 25 | $-2.61 | $2.68 | ||
| Q3 25 | $0.66 | $2.37 | ||
| Q2 25 | $-0.03 | $2.58 | ||
| Q1 25 | $0.38 | $2.48 | ||
| Q4 24 | $0.46 | $2.34 | ||
| Q3 24 | $0.12 | $2.11 | ||
| Q2 24 | $0.29 | $1.97 | ||
| Q1 24 | $0.31 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $1.4B |
| 总债务越低越好 | $1.8B | $403.9M |
| 股东权益账面价值 | $12.2B | $6.3B |
| 总资产 | $27.1B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.15× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资IVZRMD
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $973.1M | $1.4B | ||
| Q2 25 | $922.7M | $1.2B | ||
| Q1 25 | $821.7M | $932.7M | ||
| Q4 24 | $986.5M | $521.9M | ||
| Q3 24 | $1.0B | $426.4M | ||
| Q2 24 | $878.5M | $238.4M | ||
| Q1 24 | $895.7M | $237.9M |
总债务IVZRMD
| Q4 25 | $1.8B | $403.9M | ||
| Q3 25 | $1.6B | $408.7M | ||
| Q2 25 | $1.9B | $658.4M | ||
| Q1 25 | $964.8M | $663.1M | ||
| Q4 24 | $890.6M | $662.9M | ||
| Q3 24 | $890.3M | $667.6M | ||
| Q2 24 | $890.1M | $697.3M | ||
| Q1 24 | $1.3B | $997.0M |
股东权益IVZRMD
| Q4 25 | $12.2B | $6.3B | ||
| Q3 25 | $14.0B | $6.1B | ||
| Q2 25 | $13.9B | $6.0B | ||
| Q1 25 | $14.7B | $5.5B | ||
| Q4 24 | $14.6B | $5.3B | ||
| Q3 24 | $14.8B | $5.2B | ||
| Q2 24 | $14.6B | $4.9B | ||
| Q1 24 | $14.6B | $4.6B |
总资产IVZRMD
| Q4 25 | $27.1B | $8.5B | ||
| Q3 25 | $28.4B | $8.3B | ||
| Q2 25 | $28.5B | $8.2B | ||
| Q1 25 | $28.1B | $7.6B | ||
| Q4 24 | $27.0B | $7.1B | ||
| Q3 24 | $27.5B | $7.2B | ||
| Q2 24 | $27.2B | $6.9B | ||
| Q1 24 | $28.1B | $6.8B |
负债/权益比IVZRMD
| Q4 25 | 0.15× | 0.06× | ||
| Q3 25 | 0.12× | 0.07× | ||
| Q2 25 | 0.14× | 0.11× | ||
| Q1 25 | 0.07× | 0.12× | ||
| Q4 24 | 0.06× | 0.13× | ||
| Q3 24 | 0.06× | 0.13× | ||
| Q2 24 | 0.06× | 0.14× | ||
| Q1 24 | 0.09× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $455.8M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $432.2M | $311.2M |
| 自由现金流率自由现金流/营收 | 25.5% | 21.9% |
| 资本支出强度资本支出/营收 | 1.4% | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.87× |
| 过去12个月自由现金流最近4个季度 | $1.4B | $1.8B |
8季度趋势，按日历期对齐
经营现金流IVZRMD
| Q4 25 | $455.8M | $339.7M | ||
| Q3 25 | $606.2M | $457.3M | ||
| Q2 25 | $547.9M | $538.8M | ||
| Q1 25 | $-84.6M | $578.7M | ||
| Q4 24 | $316.9M | $308.6M | ||
| Q3 24 | $438.4M | $325.5M | ||
| Q2 24 | $489.1M | $440.1M | ||
| Q1 24 | $-54.4M | $402.0M |
自由现金流IVZRMD
| Q4 25 | $432.2M | $311.2M | ||
| Q3 25 | $586.4M | $414.4M | ||
| Q2 25 | $530.4M | $508.2M | ||
| Q1 25 | $-108.0M | $557.9M | ||
| Q4 24 | $309.9M | $288.0M | ||
| Q3 24 | $410.0M | $307.7M | ||
| Q2 24 | $462.4M | $415.2M | ||
| Q1 24 | $-75.4M | $380.8M |
自由现金流率IVZRMD
| Q4 25 | 25.5% | 21.9% | ||
| Q3 25 | 35.7% | 31.0% | ||
| Q2 25 | 35.0% | 37.7% | ||
| Q1 25 | -7.1% | 43.2% | ||
| Q4 24 | 19.5% | 22.5% | ||
| Q3 24 | 27.1% | 25.1% | ||
| Q2 24 | 31.2% | 33.9% | ||
| Q1 24 | -5.1% | 31.8% |
资本支出强度IVZRMD
| Q4 25 | 1.4% | 2.0% | ||
| Q3 25 | 1.2% | 3.2% | ||
| Q2 25 | 1.2% | 2.3% | ||
| Q1 25 | 1.5% | 1.6% | ||
| Q4 24 | 0.4% | 1.6% | ||
| Q3 24 | 1.9% | 1.5% | ||
| Q2 24 | 1.8% | 2.0% | ||
| Q1 24 | 1.4% | 1.8% |
现金转化率IVZRMD
| Q4 25 | — | 0.87× | ||
| Q3 25 | 1.70× | 1.31× | ||
| Q2 25 | 2.78× | 1.42× | ||
| Q1 25 | -0.49× | 1.59× | ||
| Q4 24 | 1.51× | 0.90× | ||
| Q3 24 | 7.97× | 1.05× | ||
| Q2 24 | 3.70× | 1.51× | ||
| Q1 24 | -0.38× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IVZ
| Investment Advice | $1.2B | 73% |
| Distribution And Shareholder Service | $382.7M | 23% |
| Financial Service Other | $51.0M | 3% |
| Investment Performance | $28.9M | 2% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
